PT-141 for Women: Low Libido, Vyleesi, and What to Expect
PT-141 is the only FDA-approved medication that targets sexual desire in a woman’s brain rather than blood flow in the body. Here is who it is for, what the approval actually covers, how it compares to the daily pill Addyi, and the honest answers to the questions women ask most.
In this article
Key Takeaways
- PT-141 (bremelanotide) is FDA-approved as Vyleesi specifically for low sexual desire in premenopausal women, the only approved medication that works on desire itself rather than blood flow or hormones.
- It works in the brain. PT-141 activates melanocortin pathways in the hypothalamus that drive the experience of wanting, which is why it can help when the problem is desire rather than physical arousal.
- It is non-hormonal and on-demand. You use it before anticipated intimacy, not every day, and it does not interact with estrogen, progesterone, or hormone therapy.
- The approval covers premenopausal women. Use in postmenopausal women is off-label, a legal and common practice based on a provider’s judgment, but the formal evidence base is in premenopausal women.
- The effect is meaningful for some women and modest for others. Clinical guidance is to try it about 6 to 8 times and stop if there is no clear benefit. Nausea is the most common side effect.
The Problem It Addresses
For years, low sexual desire in women was treated as a problem without a medicine. If a woman lost interest in sex and it genuinely bothered her, the options were a conversation, a guess about hormones, or being told it was in her head. Meanwhile an entire category of drugs existed for men. That imbalance is part of why PT-141 matters. It is the first and only FDA-approved medication that treats low desire in women by working on the place desire actually starts, the brain.
The clinical name for the condition is hypoactive sexual desire disorder, or HSDD: persistently low sexual desire that causes real personal distress and is not explained by a medical condition, a medication, or relationship problems. It is estimated to affect roughly 10% of premenopausal women. The distress part is the key. This is not about a number on a chart. It is about women for whom the loss of desire is a genuine source of unhappiness.
The FDA approval, in one line
PT-141 (bremelanotide) was approved by the FDA in 2019 under the brand name Vyleesi, specifically for acquired, generalized HSDD in premenopausal women. It is the only approved medication that targets sexual desire itself rather than blood flow or hormone levels.
What the FDA Approval Covers
The approval rests on two large Phase III trials called RECONNECT, which enrolled over 1,200 premenopausal women with HSDD. Women using bremelanotide showed statistically significant increases in desire and decreases in the distress tied to low desire, taken on-demand before anticipated activity rather than daily. The full regulatory picture is covered in our PT-141 FDA status guide, but the short version is that this is a properly approved medication with real trial evidence behind it, not a gray-market compound.
Kingsberg SA et al., "Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials" (RECONNECT), Obstet Gynecol, 2019. View study
How It Works in a Woman’s Brain
Most treatments touching female sexual function work on the body: lubrication, blood flow, hormones. PT-141 works upstream of all of that. It activates melanocortin-4 receptors in the hypothalamus, the brain region that governs sexual motivation, which sets off the dopamine signaling behind wanting. In plain terms, it works on desire at the source rather than trying to fix a downstream symptom.
Brain-imaging research backs this up. In studies of women with HSDD, a melanocortin agonist of the same class increased reported desire and changed activity in brain regions tied to sexual processing, compared with placebo. This central mechanism is also why PT-141 is non-hormonal: it never touches estrogen or progesterone, so it can generally sit alongside hormone therapy without interaction concerns. For the deeper science, the main PT-141 guide covers the mechanism in full.
Thurston L et al., "Melanocortin 4 receptor agonism enhances sexual brain processing in women with HSDD," J Clin Invest, 2022. View study
PT-141 vs Addyi
There is one other FDA-approved medication for HSDD in premenopausal women: Addyi (flibanserin), a daily pill. Women researching their options are really choosing between these two, so here is the honest comparison.
| PT-141 (Vyleesi) | Addyi (flibanserin) | |
|---|---|---|
| Form | On-demand injection | Daily pill |
| When you take it | ~45-60 min before activity | Every day, at bedtime |
| How it works | Melanocortin desire pathway | Serotonin/dopamine balance over time |
| Alcohol | No specific daily restriction | Serious interaction, caution required |
| Time to effect | Same session | Weeks of daily use |
| Main side effect | Nausea | Dizziness, sleepiness, low blood pressure |
Neither is better in the abstract. Addyi suits a woman who would rather take a daily pill and not think about timing, provided the alcohol caution fits her life. PT-141 suits a woman who would rather dose on her own terms before intimacy and skip a daily commitment. The on-demand nature is the main reason many women prefer it.
Premenopausal vs After Menopause
This is the question competitors tend to gloss over, so it is worth being direct about. The FDA approval is for premenopausal women. That is the population the RECONNECT trials studied, and it is what the label covers.
If you are postmenopausal
Use of PT-141 after menopause is off-label. That is not a loophole or a warning sign. Off-label prescribing, where a provider uses an approved drug for a situation outside the exact label based on clinical judgment, is legal and routine across medicine. What it does mean is that the formal trial evidence is in premenopausal women, so the decision is more individualized. A good provider will talk through your overall health, other contributors to low desire, and whether PT-141 is a reasonable fit for you specifically.
What to Expect
Two honest expectations to set. First, the effect is real but not universal. In the trials it was statistically significant, and for some women clearly meaningful, while for others the benefit was modest. Clinical guidance is to try PT-141 about 6 to 8 times to judge your response, and to stop if there is no clear improvement. It works best when low desire is genuinely the main issue, not when the real drivers are stress, relationship strain, or another medical cause.
Second, plan for nausea. It is the most common side effect, affecting roughly 40% of women, usually mild and often fading with repeated use. Eating light around dosing helps, and your provider may suggest a pre-dose anti-nausea option. The full side-effect breakdown and how to minimize each one is in our PT-141 side effects guide, and the practical timing and injection steps are in how to use PT-141. PeRx ships it as a ready-to-use subcutaneous injection, so there is nothing to prepare.
Frequently Asked Questions
Related Guides
Continue reading about peptides and protocols that pair well with this guide.
PT-141 (Bremelanotide): Dosage, Effects & Access
PT-141 (bremelanotide) is the only FDA-approved medication that targets sexual desire in the brain rather than blood flow in the body. The 2026 guide to how it works, the 1.75-2mg dosage protocol, what to expect from the nausea, and how it compares to Viagra, plus the tanning-drug origin story that's one of the best in pharma.
How to Use PT-141: Timing, Injection, and What to Expect
PT-141 is an on-demand peptide, so the practical questions are about timing more than anything else. Here is when to inject before activity, the step-by-step subcutaneous technique, how long the effects last, and how often you can dose.
Does PT-141 Come in a Pill? Oral vs Injectable PT-141
PT-141 shows up online as troches, capsules, and nasal sprays, not just injections. The catch is that a peptide has to survive your gut and reach your bloodstream to do anything. Here is how the oral, nasal, and subcutaneous forms actually compare.
Ready to get started?
Pharmaceutical-grade PT-141, prescribed by a licensed provider and delivered ready to use.
Medical Disclaimer
The information provided on this website, including all articles, guides, and educational content, is for informational and educational purposes only and is not intended as medical advice, diagnosis, or treatment. Nothing on this site should be construed as a substitute for professional medical advice from a qualified healthcare provider.
The majority of peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the indications described. They are classified as bulk drug substances and are available only through a licensed prescribing provider and compounding pharmacy. All treatments require a valid prescription and provider oversight.
The majority of published research on peptide therapies has been conducted in preclinical (animal) models. While early human data is encouraging, comprehensive clinical trial data remains limited for most peptide compounds. Individual results may vary significantly based on health status, injury type, and other factors. No specific outcomes are guaranteed.
Certain peptides discussed on this site are classified as prohibited substances by the World Anti-Doping Agency (WADA) and are banned by major sports organizations including the NFL, NCAA, UFC, NBA, MLB, NHL, and PGA. If you are subject to anti-doping testing, consult your governing body before considering any peptide therapy.
Statements on this website have not been evaluated by the Food and Drug Administration. Products and therapies discussed are not intended to diagnose, treat, cure, or prevent any disease.
© 2026 Wellness MD Group PC DBA PeRx. All rights reserved.
Reviewed by Dr. Cory Mellon, MD · Last reviewed June 2026